WO2008010362A1 - Powder of vitamin e/proline complex and method of producing the same - Google Patents
Powder of vitamin e/proline complex and method of producing the same Download PDFInfo
- Publication number
- WO2008010362A1 WO2008010362A1 PCT/JP2007/061686 JP2007061686W WO2008010362A1 WO 2008010362 A1 WO2008010362 A1 WO 2008010362A1 JP 2007061686 W JP2007061686 W JP 2007061686W WO 2008010362 A1 WO2008010362 A1 WO 2008010362A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- powder
- proline
- comparative example
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- vitamin E and proline are stirred in an organic solvent to form a complex of vitamin E and proline, and the organic solvent is distilled off and dried to obtain a high vitamin E content, and
- the present invention relates to a flowable powder and a method for producing the same.
- Vitamin E which is viscous and oily, is used for the primary prevention of coronary artery disease such as myocardial infarction (Lancet 356: 1213-1218, 2000 (Non-patent Document 1)) in human subjects. In contrast to the prevention of prostate cancer (J Natl Cancer Inst 90: 440-6, 1998 (Non-Patent Document 2)). In addition, suppression of the decline in the cognitive function of Alzheimer (Dimentia 1: 134-142, 1987 ( It is judged to be effective against non-patent literature 3)). There are many literatures that prevent diseases other than the above by taking vitamin E alone or in combination with vitamin C or zinc.
- vitamin E is oily at room temperature, and it is also fat-soluble and extremely viscous, so it must be devised when used in pharmaceuticals and foods.
- vitamin E is changing the form of vitamin E into a powder, and by making it into a powder, it can be easily mixed uniformly into pharmaceuticals and food materials, and is an extremely effective method for processing into products. It is.
- Patent Document 2 JP-A-6 4-6 6 1 4 17 (Patent Document 3), JP-A 8-14 3 45 6 (Patent Document 4), JP-A-10 10 — 1 2 7 2 5 8 (Patent Document 5), Japanese Patent Laid-Open No. 1 1-1 9 3 No. 229 (Patent Document 6), JP-A 2000-247869 (Patent Document 7), JP-A 2004-75600 (Patent Document 8)) and the like have been reported.
- any of the methods using emulsified powder has the disadvantage that it is difficult to obtain a powder containing a high amount of vitamin E, and that the fluidity of the powder becomes very poor when the content is high.
- Patent Document 1 Japanese Patent Application Laid-Open No. Sho 60-1 78 8 82
- Patent Document 2 Japanese Patent Application Laid-Open No. Sho 6 1 1 6 06 1 9
- Patent Document 3 Japanese Patent Application Laid-Open No. 64-6 14 1 7
- Patent Document 4 Japanese Patent Application Laid-Open No. 8-1 4 34 5 6
- Patent Document 5 Japanese Patent Application Laid-Open No. 1 0-1 27 2 58
- Patent Document 6 Japanese Patent Laid-Open No. 1 1 1 1 93 2 29
- Patent Document 7 Japanese Unexamined Patent Publication No. 2000-24 7 86 9
- Patent Document 8 Japanese Unexamined Patent Application Publication No. 2004-75 600
- Non-Patent Document 1 Lancet ⁇ 5: 1213-1218, 2000
- Non-Patent Document 2 J Natl Cancer Inst 90: 440-6, 1998
- Non-Patent Document 3 Dimentia 1; 134-142, 1987 Disclosure of the Invention
- An object of the present invention is to find and produce vitamin E that is oily at room temperature, fat-soluble and extremely viscous, and that has a high vitamin E content and good fluidity.
- the present inventor formed a complex of vitamin E and proline by mixing vitamin E, proline and an organic solvent and stirring at room temperature to heating.
- the present inventors have found that a powder having a high vitamin E content and good fluidity can be obtained by distilling off the organic solvent and drying, thereby completing the present invention.
- a vitamin E-containing powder obtained by forming a complex by stirring vitamin E and proline in an organic solvent, distilling off the organic solvent and drying;
- a method for producing a vitamin E-containing powder characterized in that a complex is formed by stirring vitamin E and proline in an organic solvent, the organic solvent is distilled off and dried.
- Vitamin E used in the present invention is natural vitamin E extracted or purified from soybean or rapeseed seeds or palm oil, or synthetic vitamin E.
- Proline used in the present invention is one of 20 amino acids that are constituents of proteins that form the human body, and is a major component of collagen that constitutes the skin and the like.
- General properties include a structure with a heterocycle, weak sweetness, physiological activity such as lipolytic enzyme lipase activation, collagen synthesis promoting activity and epidermal cell growth promoting activity, and immediate effect Energy source.
- the object of the present invention is to obtain a powder having a high vitamin E content and good fluidity.
- the weight of vitamin E is 1 and proline is lower than 0.27 in terms of weight, the powder
- the organic solvent used in the present invention is alcohols such as methanol, ethanol, propanol, and butanol, and any of them can dissolve vitamin E and proline. It is preferable to use ethanol.
- the amount of ethanol is preferably 10 times the amount (V / W) or more of the amount of vitamin E and proline charged.
- the powder having high vitamin E content and good fluidity of the present invention can be produced by the method described below, but is not limited thereto.
- Vitamin E, proline, and ethanol are placed in a tank equipped with a heating or heating device and stirred for a specified time while heating. After that, the ethanol is distilled off and then dried.
- Ethanol is distilled off using a general apparatus such as a distillation or vacuum distillation apparatus, and powder is dried using a general apparatus such as spray drying, drum drying, belt drying or freeze dryer. Can do.
- the powder thus obtained has a high vitamin E content and good powder flowability.
- This powder is effective in the primary prevention of coronary artery disease such as myocardial infarction, prevention of prostate cancer, and suppression of decline in Alzheimer's cognitive function. Can be used for expected usage.
- Figure 1 shows a powder consisting of a complex of vitamin E and proline.
- Vitamin E (trade name: d- ⁇ -tocopherol Tama Seikagaku Co., Ltd.) 5 g
- proline (trade name: L (1) monoproline Wako Pure Chemical Industries, Ltd.) 5 g
- 180 ml of ethanol was weighed into an eggplant-shaped flask and heated at 75 ° C. for 3 hours. Subsequently, ethanol was distilled off under reduced pressure and then dried under reduced pressure to obtain 10 g of white to light yellow powder.
- the ratio of vitamin E to proline was 1: 1, and the content of vitamin E was 50%.
- Vitamin E (trade name: d— ⁇ -tocopherol, manufactured by Tama Seikagaku) 6 g
- proline trade name: L (1) —proline, manufactured by Wako Pure Chemical Industries, Ltd.
- 150 ml of ethanol was weighed into an eggplant flask and heated at 75 ° C for 3 hours. Subsequently, ethanol was distilled off under reduced pressure and then dried under reduced pressure to obtain 10 g of white to light yellow powder.
- the ratio of vitamin E to proline was 1: 0.67, and the content of vitamin E was 60%.
- Vitamin E (trade name: d— ⁇ -tocopherol Tama Seikagaku Co., Ltd.) 7 g
- proline (trade name: L (1) monoproline, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g
- 100 ml of ethanol was weighed into an eggplant flask and heated at 75 ° C. for 3 hours. Subsequently, ethanol was distilled off under reduced pressure and then dried under reduced pressure to obtain 10 g of white to light yellow powder.
- the ratio of vitamin E to proline was 1: 0.43, and the content of vitamin E was 70%.
- Vitamin E (trade name: d- ⁇ -tocopherol Tama Seikagaku Co., Ltd.) 7.8 g
- proline (trade name: L (1) monoproline Wako Pure Chemical Industries, Ltd. ) 2.2 g of ethanol 10 O m 1 was weighed into an eggplant type flask and heated at 75 ° C. for 3 hours. Next, ethanol was distilled off under reduced pressure and then dried under reduced pressure to obtain 10 g of white to pale yellow powder (FIG. 1).
- the ratio of vitamin E to proline is 1: 0.28 and the content of vitamin E is 78. /. Met.
- Vitamin E (trade name: d— ⁇ -tocofol roll manufactured by Tama Seikagaku Co., Ltd.) 9.1 g
- proline (trade name: L (1) monoproline, manufactured by Wako Pure Chemical Industries, Ltd.) ) 0.9 g of ethanol 5 O m 1 was weighed into an eggplant type flask and heated at 75 ° C. for 3 hours. Next, ethanol was distilled off under reduced pressure and then dried under reduced pressure to obtain 10 g of white to pale yellow powder, but the fluidity of the powder was not good.
- Example 1 Example 2
- Example 3 Example 4 Comparative Example 1 Vitamin E (g) 5 6 7 7.8 9.1 Proline (g) 5 4 3 2.2 0.9 Ethanol (ml) 180 150 100 100 50
- proline is the same amino acid L-alanine (trade name: L
- proline is the same amino acid L-tributofan (trade name: L-tributophane manufactured by Wako Pure Chemical Industries, Ltd.) 4 g (comparative example 1 7), or L-cystine (trade name: L Iscystine Wako Pure Chemical Industries, Ltd.) 4 g (Comparative Example 1 8)
- L-tributofan trade name: L-tributophane manufactured by Wako Pure Chemical Industries, Ltd.
- L-cystine trade name: L Iscystine Wako Pure Chemical Industries, Ltd.
- Ethanol was distilled off. 'Dry state after drying' Vitamin E and the amino acid were mixed and oily. Instead of proline, it was tested whether 17 amino acids listed in Table 2 could form a complex with vitamin E. However, in any experiment, it was not possible to make a powder. E and proline were found to form a complex specifically into a powder.
- Example 4 Using the powder obtained in Example 4, measurement of physical properties such as vitamin E content in powder, repose angle, bulk density, tapping density and melting point was performed.
- the measurement method of vitamin E content in powder is 40 times the amount of powder (VZW) Distribute with 50 vo 1% ethanol water and 20 times the amount of hexane (V / W), and evaporate the hexane to dry out to obtain a viscous oil.
- the melting point of the powder is MI CRO MELT I NG PO I NT AP PARATU
- the powder of the present invention of Example 4 has a vitamin E content of 78%, an angle of repose of 39 °, a bulk density of 0.44 gZm 1, a tapping density of 0.53 g Zm 1 and a melting point. It can be seen that the powder has a high vitamin E content and good fluidity at 63 to 65 ° C. Industrial applicability
- a powder having a high vitamin E content and good fluidity can be produced, and a powder suitable for production of pharmaceuticals and foods can be obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
明 細 書 ビタミン Eとプロリンの複合体粉末及ぴその製造方法 技術分野 Description: Vitamin E and proline complex powder and its manufacturing method Technical Field
本発明は、 ビタミン Eとプロリンを有機溶媒中で攪拌することによって、 ビタ ミン Eとプロリンの複合体を形成させ、 有機溶媒を留去、 乾燥させて得られるビ タミン E含量が高く、 且つ、 流動性の良い粉末とその製造方法に関する。 背景技術 In the present invention, vitamin E and proline are stirred in an organic solvent to form a complex of vitamin E and proline, and the organic solvent is distilled off and dried to obtain a high vitamin E content, and The present invention relates to a flowable powder and a method for producing the same. Background art
粘稠で油状であるビタミン Eは、 人を対象とした試験において、 心筋梗塞のよ うな冠状動脈疾患などの一次予防 (Lancet 356 : 1213-1218, 2000 (非特許文献 1 ) ) に対して、 前立腺癌の予防 (J Natl Cancer Inst 90 : 440-6, 1998 (非特許文献 2 ) ) に対して、. さ らにはアルツハイマーの認識機能の衰えの抑制 (Dimentia 1: 134-142, 1987 (非特許文献 3 ) ) に対して有効であると判断されている。 上記以 外の疾患に対しても、 ビタミン E単独、 あるいはビタミン Cや亜鉛などと併用し て摂取することによって、 予防効果があるとの文献が多数ある。 Vitamin E, which is viscous and oily, is used for the primary prevention of coronary artery disease such as myocardial infarction (Lancet 356: 1213-1218, 2000 (Non-patent Document 1)) in human subjects. In contrast to the prevention of prostate cancer (J Natl Cancer Inst 90: 440-6, 1998 (Non-Patent Document 2)). In addition, suppression of the decline in the cognitive function of Alzheimer (Dimentia 1: 134-142, 1987 ( It is judged to be effective against non-patent literature 3)). There are many literatures that prevent diseases other than the above by taking vitamin E alone or in combination with vitamin C or zinc.
しかしながらビタミン Eは、 常温で油状であり、 さらには脂溶性で粘性が極め て高いため、 医薬品及び食品へ用いる際には工夫を要する。 However, vitamin E is oily at room temperature, and it is also fat-soluble and extremely viscous, so it must be devised when used in pharmaceuticals and foods.
一例としては、 ビタミン Eを粉末へと形態変化させることであり、 粉末にする ことによって、 容易に医薬品及ぴ食品素材へ均一に混合することができ、 商品へ と加工する上で極めて有効な方法である。 One example is changing the form of vitamin E into a powder, and by making it into a powder, it can be easily mixed uniformly into pharmaceuticals and food materials, and is an extremely effective method for processing into products. It is.
ゆえに、 ビタミン Eを粉末にする特許が多数あり、 例えば乳化剤、 ゼラチン及 ぴカゼインナトリウム等のタンパク質、 アラビアガム等のガム類、 単糖及び二糖 等の糖類、 糖アルコール、 サポニン、 化工澱粉及びデキストリン等の多糖類を単 独あるいは複合させて用いることで乳化粉末にする特許 (特開昭 6 0 - 1 7 8 8 8 2号公報 (特許文献 1 )、 特開昭 6 1— 6 0 6 1 9号公報 (特許文献 2 )、 特開 昭 6 4— 6 1 4 1 7号公報 (特許文献 3 )、特開平 8— 1 4 3 4 5 6号公報(特許 文献 4 )、 特開平 1 0— 1 2 7 2 5 8号公報 (特許文献 5 )、 特開平 1 1 _ 1 9 3 229号公報(特許文献 6)、特開 2000-24786 9号公報(特許文献 7)、 特開 2004— 75600号公報 (特許文献 8)) などが報告されている。 Therefore, there are many patents for powdering vitamin E, such as emulsifiers, proteins such as gelatin and sodium caseinate, gums such as gum arabic, saccharides such as monosaccharides and disaccharides, sugar alcohols, saponins, modified starches and dextrins Patents for making emulsified powders by using single or complex polysaccharides (JP-A-60-0-178888-2 (Patent Document 1), JP-A-6-1-6001 No. 9 (Patent Document 2), JP-A-6 4-6 6 1 4 17 (Patent Document 3), JP-A 8-14 3 45 6 (Patent Document 4), JP-A-10 10 — 1 2 7 2 5 8 (Patent Document 5), Japanese Patent Laid-Open No. 1 1-1 9 3 No. 229 (Patent Document 6), JP-A 2000-247869 (Patent Document 7), JP-A 2004-75600 (Patent Document 8)) and the like have been reported.
しかしながら乳化粉末による方法では、 何れもビタミン Eを高含有させた粉末 とするには困難であり、 さらには高含有させると粉体の流動性が非常に悪くなる という欠点を有していた。 However, any of the methods using emulsified powder has the disadvantage that it is difficult to obtain a powder containing a high amount of vitamin E, and that the fluidity of the powder becomes very poor when the content is high.
特許文献 1 特開昭 60— 1 78 8 82号公報 Patent Document 1 Japanese Patent Application Laid-Open No. Sho 60-1 78 8 82
特許文献 2 特開昭 6 1一 6 06 1 9号公報 Patent Document 2 Japanese Patent Application Laid-Open No. Sho 6 1 1 6 06 1 9
特許文献 3 特開昭 64— 6 14 1 7号公報 Patent Document 3 Japanese Patent Application Laid-Open No. 64-6 14 1 7
特許文献 4 特開平 8— 1 4 34 5 6号公報 Patent Document 4 Japanese Patent Application Laid-Open No. 8-1 4 34 5 6
特許文献 5 特開平 1 0— 1 27 2 58号公報 Patent Document 5 Japanese Patent Application Laid-Open No. 1 0-1 27 2 58
特許文献 6 特開平 1 1一 1 93 2 29号公報 Patent Document 6 Japanese Patent Laid-Open No. 1 1 1 1 93 2 29
特許文献 7 特開 2000 ― 24 7 86 9号公報 Patent Document 7 Japanese Unexamined Patent Publication No. 2000-24 7 86 9
特許文献 8 特開 2004 ― 75 6 00号公報 Patent Document 8 Japanese Unexamined Patent Application Publication No. 2004-75 600
非特許文献 1 Lancet ^5 :1213 - 1218, 2000 Non-Patent Document 1 Lancet ^ 5: 1213-1218, 2000
非特許文献 2 J Natl Cancer Inst 90: 440-6, 1998 Non-Patent Document 2 J Natl Cancer Inst 90: 440-6, 1998
非特許文献 3 Dimentia 1; 134-142, 1987 発明の開示 Non-Patent Document 3 Dimentia 1; 134-142, 1987 Disclosure of the Invention
本発明の課題は、常温で油状であり、脂溶性で粘性が極めて高いビタミン Eを、 ビタミン E含量が高く、 且つ、 流動性の良い粉末を見出し製造することである。 本発明者は、 上記課題を達成するために鋭意検討を重ねた結果、 ビタミン Eと プロリンと有機溶媒を配合し、 室温乃至加熱しながら攪拌することによってビタ ミン Eとプロリンの複合体を形成させ、 有機溶媒を留去、 乾燥させることで、 ビ タミン E含量が高く、 且つ、 流動性の良い粉末になることを見出し、 本発明を完 成するに至った。 An object of the present invention is to find and produce vitamin E that is oily at room temperature, fat-soluble and extremely viscous, and that has a high vitamin E content and good fluidity. As a result of intensive studies in order to achieve the above-mentioned problems, the present inventor formed a complex of vitamin E and proline by mixing vitamin E, proline and an organic solvent and stirring at room temperature to heating. The present inventors have found that a powder having a high vitamin E content and good fluidity can be obtained by distilling off the organic solvent and drying, thereby completing the present invention.
すなわち本発明は、 That is, the present invention
(1) 有機溶媒中で、 ビタミン Eとプロリンを攪拌することによって複合体を形 成し、 有機溶媒を留去、 乾燥させて得られるビタミン E含有粉末、 (1) A vitamin E-containing powder obtained by forming a complex by stirring vitamin E and proline in an organic solvent, distilling off the organic solvent and drying;
(2) ビタミン Eに対するプロリンの重量比が、 1 : 0. 27〜: 1 : 0. 6 7で あることを特徴とする (1 ) 記載のビタミン E含有粉末、 (2) The weight ratio of proline to vitamin E is 1: 0.27 ~: 1: 0.67 (1) The vitamin E-containing powder according to (1),
( 3 ) 有機溶媒中で、 ビタミン Eとプロリンを攪拌することによって複合体を形 成し、 有機溶媒を留去、 乾燥させることを特徴とするビタミン E含有粉末の製造 方法、 (3) A method for producing a vitamin E-containing powder characterized in that a complex is formed by stirring vitamin E and proline in an organic solvent, the organic solvent is distilled off and dried.
( 4 ) ビタミン Eに対するプロリンの重量比が、 1 : 0 . 2 7〜 1 : 0 . 6 7で あることを特徴とする (3 ) 記載のビタミン E含有粉末の製造方法 (4) The method for producing a vitamin E-containing powder according to (3), wherein the weight ratio of proline to vitamin E is 1: 0.27 to 1: 0.67
に関するものである。 It is about.
本発明者が、 ビタミン Eの粉末化にあたって、 ビタミン Eと混合させる物質と して、 食品添加物の一種から選択すべく検討したところ、 アミノ酸が好ましいと 判断した。 When the present inventor studied to select one of the food additives as a substance to be mixed with vitamin E when powdering vitamin E, it was determined that amino acids are preferable.
しかし、 アミノ酸も多種あるところいろいろ実験を重ねた結果、 プロリンのみ が粉末化可能であることを見出し、 本発明を完成させた。 However, as a result of repeated experiments with various amino acids, it was found that only proline can be powdered, and the present invention was completed.
本発明で用いるビタミン Eは、 大豆及び菜種などの種子あるいはパーム油脂か ら抽出精製された天然ビタミン E、 あるいは合成ビタミン Eであり、 d— α—ト コフェローノレ、 d— j8 — トコフェローノレ、 d _ γ — トコフェローノレ、 d— δ — ト コフェローノレ、 d— α—トコトリエノーノレ、 d— j3 _トコトリエノーノレ、 d— 一トコトリエノ一ノレ、 d— δ —トコ トリエノ一ノレ及び d 1 — ひ 一トコフエ口一ノレ の内 1または 2以上の混合物である。 該ビタミン Eは、 常温で油状であり、 さら には脂溶性で粘性が極めて高い。 Vitamin E used in the present invention is natural vitamin E extracted or purified from soybean or rapeseed seeds or palm oil, or synthetic vitamin E. d- α- tocopheronole, d-j8-tocopheronole, d _ γ — Tocopheronole, d— δ — Tocopheronole, d— α— Tocotrienore, d— j3 _ Tocotrienole, d— One Tocotrieno One, d— δ — Toco Trieno One and d 1 — A mixture of 1 or 2 of 1 Tokofue mouths. Vitamin E is oily at room temperature, and is fat-soluble and extremely viscous.
本発明で用いるプロリンは、 人体を形成するタンパク質の構成成分である 2 0 種類のアミノ酸の一種であり、皮膚などを構成するコラーゲンの主要成分である。 一般的な性質は、 複素環を有した構造であり、 弱い甘味を呈し、 脂肪分解酵素リ パーゼの活性化、 コラーゲン合成促進活性及び表皮細胞増殖促進活性などの生理 活性を示し、 さらには即効性のエネルギー源となる。 Proline used in the present invention is one of 20 amino acids that are constituents of proteins that form the human body, and is a major component of collagen that constitutes the skin and the like. General properties include a structure with a heterocycle, weak sweetness, physiological activity such as lipolytic enzyme lipase activation, collagen synthesis promoting activity and epidermal cell growth promoting activity, and immediate effect Energy source.
ビタミン Eとプロリンの比率は、 重量換算でビタミン E :プロリン = 1 : 0 . The ratio of vitamin E and proline is Vitamin E: proline = 1 in weight conversion.
1〜 1 : 1 0であることが好ましく、 より好ましくは、 ビタミン E :プロリン =1-1: 10 is preferable, more preferably vitamin E: proline =
1 : 0 . 2 7〜 1 : 0 . 6 7である。 本発明は、 ビタミン E含量が高く、 且つ、 流動性の良い粉末を得ることが目的であり、 重量換算でビタミン Eが 1に対して プロリンが 0 . 2 7よりも低い場合には、 粉体の流動性が悪くなり、 重量換算で ビタミン Eが 1に対してプロリンが 0 . 6 7よりも高い場合には、 ビタミン Eの 含量が低下してくる。 1: 0.27 to 1: 0.67. The object of the present invention is to obtain a powder having a high vitamin E content and good fluidity. When the weight of vitamin E is 1 and proline is lower than 0.27 in terms of weight, the powder The fluidity of When vitamin E is 1 and proline is higher than 0.67, the content of vitamin E decreases.
本発明で用いる有機溶媒は、 メタノール、 エタノール、 プロパノール及びブタ ノール等のアルコール類であり、 ビタミン Eとプロリンを溶解させるものである ならば何れを用いてもかまわないが、 食品への用途を考えると、 エタノールを用 いることが好ましい。 The organic solvent used in the present invention is alcohols such as methanol, ethanol, propanol, and butanol, and any of them can dissolve vitamin E and proline. It is preferable to use ethanol.
エタノール量は、 ビタミン Eとプロリンの仕込み量に対して 1 0倍量(V/W) 以上であることが好ましい。 The amount of ethanol is preferably 10 times the amount (V / W) or more of the amount of vitamin E and proline charged.
本発明のビタミン E含量が高く、 且つ、 流動性の良い粉末は、 以下に述べる方 法で製造ができるが、 これに限定されるものではない。 ビタミン E、 プロリン及 びエタノールを、 加温あるいは加熱装置が取り付けられているタンクに所定量を 入れ、 加温しながら所定時間攪拌した後、 エタノールを留去し、 次いで乾燥させ る。 エタノールの留去は、 蒸留あるいは減圧蒸留装置などの一般的な装置を用い て行い、 粉末の乾燥は、 噴霧乾燥、 ドラム乾燥、 ベルト乾燥あるいは凍結乾燥機 などの一般的な装置を用いて行うことができる。 The powder having high vitamin E content and good fluidity of the present invention can be produced by the method described below, but is not limited thereto. Vitamin E, proline, and ethanol are placed in a tank equipped with a heating or heating device and stirred for a specified time while heating. After that, the ethanol is distilled off and then dried. Ethanol is distilled off using a general apparatus such as a distillation or vacuum distillation apparatus, and powder is dried using a general apparatus such as spray drying, drum drying, belt drying or freeze dryer. Can do.
かくして得られる粉末は、 ビタミン E含量が高く、 粉体の流動性が良い。 この 粉末は、 ビタミン Eが心筋梗塞のような冠状動脈疾患などの一次予防、 前立腺癌 の予防、 さらにはアルツハイマーの認識機能の衰えの抑制に対して有効であるこ と力 ら、 その生理的機能を期待した使用方法に採用できる。 The powder thus obtained has a high vitamin E content and good powder flowability. This powder is effective in the primary prevention of coronary artery disease such as myocardial infarction, prevention of prostate cancer, and suppression of decline in Alzheimer's cognitive function. Can be used for expected usage.
本明細書は本願の優先権の基礎である日本国特許出願 2006-195602号の明細書 および/ /または図面に記載される内容を包含する。 図面の簡単な説明 This specification includes the contents described in the specification and / or drawings of Japanese Patent Application No. 2006-195602, which is the basis of the priority of the present application. Brief Description of Drawings
図 1は、 ビタミン Eとプロリンとの複合体からなる粉末を示す図。 発明を実施するための最良の形態 Figure 1 shows a powder consisting of a complex of vitamin E and proline. BEST MODE FOR CARRYING OUT THE INVENTION
以下に本発明の実施例及び比較例を挙げて、 より詳細に説明するが、 本発明は それらに限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to examples and comparative examples, but the present invention is not limited thereto.
実施例 1 表 1の配合に準じ、 ビタミン E (商品名 : d— α—トコフエロール タマ生化 学 (株)製) 5 g、 プロリン (商品名: L (一) 一プロリン 和光純薬工業 (株)製) 5 g、 エタノール 1 8 0 m lをナス型フラスコに量りとり、 7 5 °Cで 3時間加熱 した。 次いで、 エタノールを減圧留去した後、 減圧乾燥させると、 白色から淡黄 色の粉末を 1 0 g得た。 . 本実施例は、 ビタミン Eとプロリンの比が 1 : 1であり、 ビタミン Eの含量が 5 0 %であった。 Example 1 Vitamin E (trade name: d-α-tocopherol Tama Seikagaku Co., Ltd.) 5 g, proline (trade name: L (1) monoproline Wako Pure Chemical Industries, Ltd.) 5 g, 180 ml of ethanol was weighed into an eggplant-shaped flask and heated at 75 ° C. for 3 hours. Subsequently, ethanol was distilled off under reduced pressure and then dried under reduced pressure to obtain 10 g of white to light yellow powder. In this example, the ratio of vitamin E to proline was 1: 1, and the content of vitamin E was 50%.
実施例 2 Example 2
表 1の配合に準じ、 ビタミン E (商品名 : d— α—トコフエロール タマ生化 学 (株)製) 6 g、 プロリン (商品名: L (一) —プロリン 和光純薬工業 (株)製) 4 g、 エタノール 1 5 0 m lをナス型フラスコに量りとり、 7 5 °Cで 3時間加熱 した。 次いで、 エタノールを減圧留去した後、 減圧乾燥させると、 白色から淡黄 色の粉末を 1 0 g得た。 Vitamin E (trade name: d—α-tocopherol, manufactured by Tama Seikagaku) 6 g, proline (trade name: L (1) —proline, manufactured by Wako Pure Chemical Industries, Ltd.) 4 g, 150 ml of ethanol was weighed into an eggplant flask and heated at 75 ° C for 3 hours. Subsequently, ethanol was distilled off under reduced pressure and then dried under reduced pressure to obtain 10 g of white to light yellow powder.
本実施例は、 ビタミン Eとプロリンの比が 1 : 0 . 6 7であり、 ビタミン Eの 含量が 6 0 %であった。 In this example, the ratio of vitamin E to proline was 1: 0.67, and the content of vitamin E was 60%.
実施例 3 Example 3
表 1の配合に準じ、 ビタミン E (商品名 : d— α—トコフエロール タマ生化 学 (株)製) 7 g、 プロリン (商品名: L (一) 一プロリン 和光純薬工業 (株)製) 3 g、 エタノール 1 0 0 m lをナス型フラスコに量りとり、 7 5 °Cで 3時間加熱 した。 次いで、 エタノールを減圧留去した後、 減圧乾燥させると、 白色から淡黄 色の粉末を 1 0 g得た。 Vitamin E (trade name: d— α-tocopherol Tama Seikagaku Co., Ltd.) 7 g, proline (trade name: L (1) monoproline, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g, 100 ml of ethanol was weighed into an eggplant flask and heated at 75 ° C. for 3 hours. Subsequently, ethanol was distilled off under reduced pressure and then dried under reduced pressure to obtain 10 g of white to light yellow powder.
本実施例は、 ビタミン Eとプロリンの比が 1 : 0 . 4 3であり、 ビタミン Eの 含量が 7 0 %であった。 In this example, the ratio of vitamin E to proline was 1: 0.43, and the content of vitamin E was 70%.
実施例 4 Example 4
表 1の配合に準じ、 ビタミン E (商品名 : d— α—トコフエロール タマ生化 学 (株)製) 7 . 8 g、 プロリン (商品名: L (一) 一プロリン 和光純薬工業 (株) 製) 2 . 2 g、 エタノール 1 0 O m 1をナス型フラスコに量りとり、 7 5 °Cで 3 時間加熱した。 次いで、 エタノールを減圧留去した後、 減圧乾燥させると、 白色 から淡黄色の粉末を 1 0 g得た(図 1 )。 本実施例は、 ビタミン Eとプロリンの比が 1 : 0 . 2 8であり、 ビタミン Eの 含量が 7 8。/。であった。 Vitamin E (trade name: d-α-tocopherol Tama Seikagaku Co., Ltd.) 7.8 g, proline (trade name: L (1) monoproline Wako Pure Chemical Industries, Ltd. ) 2.2 g of ethanol 10 O m 1 was weighed into an eggplant type flask and heated at 75 ° C. for 3 hours. Next, ethanol was distilled off under reduced pressure and then dried under reduced pressure to obtain 10 g of white to pale yellow powder (FIG. 1). In this example, the ratio of vitamin E to proline is 1: 0.28 and the content of vitamin E is 78. /. Met.
[比較例 1 ] [Comparative Example 1]
表 1の配合に準じ、 ビタミン E (商品名 : d— α—トコフヱロール タマ生化 学 (株)製) 9 . 1 g、 プロリン (商品名 : L (一) 一プロリン 和光純薬工業 (株) 製) 0 . 9 g、 エタノール 5 O m 1をナス型フラスコに量りとり、 7 5 °Cで 3時 間加熱した。 次いで、 エタノールを減圧留去した後、 減圧乾燥させると、 白色か ら淡黄色の粉末を 1 0 g得たが、 粉末の流動性は良くなかった。 Vitamin E (trade name: d— α-tocofol roll manufactured by Tama Seikagaku Co., Ltd.) 9.1 g, proline (trade name: L (1) monoproline, manufactured by Wako Pure Chemical Industries, Ltd.) ) 0.9 g of ethanol 5 O m 1 was weighed into an eggplant type flask and heated at 75 ° C. for 3 hours. Next, ethanol was distilled off under reduced pressure and then dried under reduced pressure to obtain 10 g of white to pale yellow powder, but the fluidity of the powder was not good.
本比較例は、 ビタミン Eとプロリンの比が 1 : 0 . 0 9 9であり、 ビタミン E の含量が 9 1 %であった。 実施例 1 実施例 2 実施例 3 実施例 4 比較例 1 ビタミン E (g) 5 6 7 7.8 9.1 プロリン (g) 5 4 3 2.2 0.9 エタノーノレ (ml) 180 150 100 100 50 In this comparative example, the ratio of vitamin E to proline was 1: 0.099, and the content of vitamin E was 91%. Example 1 Example 2 Example 3 Example 4 Comparative Example 1 Vitamin E (g) 5 6 7 7.8 9.1 Proline (g) 5 4 3 2.2 0.9 Ethanol (ml) 180 150 100 100 50
白色から淡 White to light
2 ,レ =.龄,ト虽 の白色力 淡 白色から淡 白色から淡 白色から淡 2, Les =. 龄, Tou 白色 white power Light White to light White to light White to light
ルを田去' 後の黄色の粉末黄色の粉末黄色の粉末黄色の粉末 After leaving Ta 'yellow powder yellow powder yellow powder yellow powder
Λ¾ になった。 になった。 になった。 になった。 ^ b Λ¾ . Became. Became. Became. ^ b
かつ†こ。 And † this.
〔比較例 2 ] [Comparative Example 2]
表 2の配合に準じ、 プロリンを同じアミノ酸であるグリシン (商品名 : グリシ ン 和光純薬工業 (株)製) 3 gに代えた以外は実施例 3と同様の操作をしたが、 粉末にはならなかった。 According to the formulation in Table 2, the same operation as in Example 3 was performed except that proline was replaced with 3 g of glycine, which is the same amino acid (trade name: glycine manufactured by Wako Pure Chemical Industries, Ltd.). did not become.
[比較例 3〜 1 6 ] [Comparative Examples 3 to 16]
表 2の配合に準じ、 プロリンを同じアミノ酸である L—ァラニン (商品名 : L According to the formulation in Table 2, proline is the same amino acid L-alanine (trade name: L
—ァラニン 和光純薬工業(株)製) 3 g (比較例 3 )、あるいは 4ーァミノ酪酸(商 品名 : 4一アミノ酪産 和光純薬工業 (株)製) 3 g (比較例 4 )、 あるいは L—セ リン (商品名 : Lーセリン 和光純薬工業 (株)製) 3 g (比較例 5 )、 あるいは L 一パリン (商品名 : L—パリン 和光純薬工業 (株)製) 3 g (比較例 6 )、 あるい は L—スレオニン (商品名: Lースレオユン 和光純薬工業(株)製) 3 g (比較例—Alalanine Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 3), or 4-aminobutyric acid (trade name: 4 Iminobuty products Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 4), or L-Serine (trade name: L-serine, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 5), or L Iparin (product name: L-parin, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g ( Comparative Example 6) or L-Threonine (trade name: L-Suleon, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example
7 )、 あるいは L—システィン (商品名 : L一システィン 和光純薬工業(株)製) 3 g (比較例 8)、 あるいは L一口イシン (商品名 : L一口イシン 和光純薬工業 (株)製) 3 g (比較例 9)、 あるいは Lーァスパラギン (商品名 : Lーァスパラギ ン 和光純薬工業 (株)製) 3 g (比較例 1 0)、 あるいは L一リシン (商品名 : L 一リシン 和光純薬工業 (株)製) 3 g (比較例 1 1)、 あるいは L一グルタミン酸7), or L-Sistine (Product name: L-Sistine Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 8), or L Ichiguchi Ishin (trade name: L Ichiguchi Ishin, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 9), or L-Lasparagin (product name: L-Isragin Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 1 0), or L monolysine (trade name: L monolysine Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 1 1), or L monoglutamic acid
(商品名 : L一グルタミン酸 和光純薬工業 (株)製) 3 g (比較例 1 2)、 あるい は L一ヒスチジン (商品名: L—ヒスチジン 和光純薬工業 (株)製) 3 g (比較例 1 3)、 あるいは L (一) 一フエ二ルァラユン (商品名 : L (一) 一フエ二ルァラ ユン 和光純薬工業(株)製) 3 g (比較例 14)、 あるいは L ( + ) —アルギニン(Product name: L-Glutamic acid, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 1 2) or L-histidine (Product name: L-histidine, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g ( Comparative Example 1 3), or L (1) One Fualarayun (trade name: L (1) One Ferrara Yun Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 14), or L (+) —Arginine
(商品名 : L ( + ) —アルギニン 和光純薬工業 (株)製) 3 g (比較例 1 5)、 あ るいは Lーチロシン (商品名: Lーチロシン 和光純薬工業(株)製) 3 g (比較例 1 6)に代えた以外は実施例 3と同様の操作をしたが、何れも粉末にはならなかつ た。 (Product name: L (+) —Arginine Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 15) or L-tyrosine (Product name: L-tyrosine, Wako Pure Chemical Industries, Ltd.) 3 g The same operation as in Example 3 was performed except that (Comparative Example 16) was used, but none of the powders became powder.
[比較例 1 7、 1 8] [Comparative Examples 1 7, 1 8]
表 2の配合に準じ、 プロリンを同じアミノ酸である L一トリブトファン (商品 名 : L一トリブトファン 和光純薬工業 (株)製) 4 g (比較例 1 7)、 あるいは L 一シスチン (商品名 : L一シスチン 和光純薬工業 (株)製) 4 g (比較例 1 8)に 代えた以外は実施例 2と同様の操作をしたが、 何れも粉末にはならなかった。 According to the composition of Table 2, proline is the same amino acid L-tributofan (trade name: L-tributophane manufactured by Wako Pure Chemical Industries, Ltd.) 4 g (comparative example 1 7), or L-cystine (trade name: L Iscystine Wako Pure Chemical Industries, Ltd.) 4 g (Comparative Example 1 8) The procedure was the same as in Example 2 except that the powder was not changed into powder.
表 2 Table 2
比較例 2 比較例 3 比較例 4 比較例 5 比較例 6 ビタミン E (g) 7 7 7 7 7 グリシン ) 3 ― 一 一 一Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Comparative Example 6 Vitamin E (g) 7 7 7 7 7 Glycine 3)
Lーァラニン (g) ― 3 — ― ―L-alanine (g) ― 3 ― ― ―
4ーァミノ酪酸 (g) ― 一 3 — 一4-aminobutyric acid (g) ― One 3 — One
L—セリン (g) ― ― 一 3 —L-Serine (g) ― ― 1 3 ―
Lーノ リン (g) ― ― 一 一 3 エタノ一ル (ml) 100 100 100 100 100 エタノールを留去.乾燥後の状態 ビタミン Eと該アミノ酸が混合した状態であり、油状で った。 L-linoline (g) ― ― 1 3 Ethanol (ml) 100 100 100 100 100 Ethanol was distilled off. State after drying Vitamin E and the amino acid were mixed and oily.
比較例 7 比較例 8 比較例 9 比較例 10 比較例 11 ビタミン E (g) 7 7 7 7 7 Comparative Example 7 Comparative Example 8 Comparative Example 9 Comparative Example 10 Comparative Example 11 Vitamin E (g) 7 7 7 7 7
L一スレ才ニン(g) 3 一 — 一 一L One thread Nin (g) 3 1 — 1 1
L—システィン (g) ― 3 一 — 一L—Sistine (g) ― 3 One — One
L一口イシン (g) ― ― 3 — 一L bite Ishin (g) ― ― 3 — One
Lーァスパラギン (g) ― ― 一 3 —L-asparagine (g) ― ― 1 3 ―
L—リシン (g) ― ― 一 一 3 エタノール (ml) 100 100 100 100 100 エタノールを留去 ·乾燥後の状態 ビタミン Eと該アミノ酸が混合した状態であり、油状であった。 L-lysine (g) ― ― 1 3 Ethanol (ml) 100 100 100 100 100 Ethanol distilled off · State after drying Vitamin E and the amino acid were mixed and oily.
比較例 12 比較例 13 比較例 14 比較例 15 比較例 16 ビタミン E (g) 7 7 7 7 7 Comparative Example 12 Comparative Example 13 Comparative Example 14 Comparative Example 15 Comparative Example 16 Vitamin E (g) 7 7 7 7 7
L—グルタミン酸 (g) 3 ― — — ―L—Glutamic acid (g) 3 — — — —
L一ヒスチジン (g) ― 3 — — ―L-histidine (g) ― 3 — — —
L (―)一フエュルァラニン (g) ― ― 3 - -L (―) One Fualanine (g) ― ― 3--
L( + )—アルギニン (g) ― ― - 3 -L (+) —Arginine (g) ― ―-3-
L—チロシン (g) ― ― 一 一 3 エタノール (ml) 100 100 100 100 100 エタノーノレを留去 ·乾燥後の状態 ビタミン Eと該アミノ酸が混合した状態であり、油状であった。 L-tyrosine (g) ― ― 1 3 Ethanol (ml) 100 100 100 100 100 Ethanol was distilled off · State after drying Vitamin E and the amino acid were mixed and oily.
比較例 17 比較例 18 Comparative Example 17 Comparative Example 18
ビタミン E (g) 6 6 Vitamin E ( g ) 6 6
L一トリブトファン (g) . 4 ― L tribute fan (g). 4 ―
L—シスチン (g) ― 4 L-cystine (g) ― 4
エタノーノレ(ml) 150 150 Ethanore (ml) 150 150
エタノールを留去 '乾燥後の状態 ビタミン Eと該アミノ酸が混合した状態であり、油状であった。 プロリンの代わりに、 表 2記載の 1 7種類のアミノ酸を用いて、 ビタミン Eと の複合体を形成できるのか実験を行ったが、 何れの実験でも粉末にすることがで きず、 このことからビタミン Eとプロリンは特異的に複合体を形成し、 粉末にな ることがわかった。 Ethanol was distilled off. 'Dry state after drying' Vitamin E and the amino acid were mixed and oily. Instead of proline, it was tested whether 17 amino acids listed in Table 2 could form a complex with vitamin E. However, in any experiment, it was not possible to make a powder. E and proline were found to form a complex specifically into a powder.
[実験例 1 ] [Experiment 1]
実施例 4において得られた粉末を用いて、 粉末中のビタミン E含量の測定、 安 息角、 カサ密度、 タッピング密度及び融点などの物性値の測定を行った。 Using the powder obtained in Example 4, measurement of physical properties such as vitamin E content in powder, repose angle, bulk density, tapping density and melting point was performed.
粉末に含まれるビタミン E含量の測定方法は、粉末に対して 4 0倍量(VZW) の 50 v o 1 %エタノール水と 20倍量 (V/W) のへキサンを用いて分配し、 へキサンを溶媒留去 ·乾燥すると粘稠な油を得るので、 この油を食品添加物公定 書第 7版記載の方法でビタミン E含量を定量し、粉末を抽出して得られた油量に、 抽出した油中のビタミン E含量を乗じて得られたビタミン E量を、 抽出時に用い た粉末量で割った値を百分率で表した値が粉末中のビタミン E含量となるので、 結果を表 3に示した。 The measurement method of vitamin E content in powder is 40 times the amount of powder (VZW) Distribute with 50 vo 1% ethanol water and 20 times the amount of hexane (V / W), and evaporate the hexane to dry out to obtain a viscous oil. Powder that uses the amount of vitamin E obtained by quantifying the vitamin E content by the method described in the 7th edition and extracting the powder multiplied by the vitamin E content in the extracted oil. The value obtained by dividing the quantity by the percentage is the vitamin E content in the powder. The results are shown in Table 3.
さらには、 粉末の流動性を調べるため、 ABD粉体特性測定器 (筒井理化学器 械 (株)製) を用いて、 安息角、 カサ密度及びタッピング密度を測定し、 結果を表 3に示した。 Furthermore, in order to investigate the fluidity of the powder, the angle of repose, the bulk density, and the tapping density were measured using an ABD powder characteristic measuring instrument (manufactured by Tsutsui Chemical Co., Ltd.). The results are shown in Table 3. .
粉末の融点は、 MI CRO MELT I NG PO I NT AP PARATU The melting point of the powder is MI CRO MELT I NG PO I NT AP PARATU
S ((株)柳本製作所製) を用いて測定し、 結果を表 3に示した。 Measurements were made using S (manufactured by Yanagimoto Seisakusho), and the results are shown in Table 3.
表 3 Table 3
実施例 4の粉末 Example 4 powder
粉末中のビタミン E含量 (%) 78 Vitamin E content in powder (%) 78
安息角 (° ) 39 Angle of repose (°) 39
カサ密度(gZml) 0.44 Bulk density (gZml) 0.44
タッピング密度 (g/ml) 0.53 Tapping density (g / ml) 0.53
融点 (°C) 63~65 Melting point (° C) 63 ~ 65
表 3の結果より、 実施例 4の本発明である粉末は、 粉末中のビタミン E含量は 78%、 安息角 39° 、 カサ密度 0. 44 gZm 1、 タッピング密度 0. 53 g Zm 1及び融点 63〜 6 5 °Cとなり、 ビタミン E含量が高く、 且つ、 流動性の良 い粉末であることがわかる。 産業上の利用可能性 From the results in Table 3, the powder of the present invention of Example 4 has a vitamin E content of 78%, an angle of repose of 39 °, a bulk density of 0.44 gZm 1, a tapping density of 0.53 g Zm 1 and a melting point. It can be seen that the powder has a high vitamin E content and good fluidity at 63 to 65 ° C. Industrial applicability
本発明によって、 ビタミン E含量が高く、 且つ、 流動性の良い粉末を作ること ができ、 医薬品及び食品の製造に適した粉末にすることができる。 According to the present invention, a powder having a high vitamin E content and good fluidity can be produced, and a powder suitable for production of pharmaceuticals and foods can be obtained.
本明細書で引用した全ての刊行物、 特許および特許出願をそのまま参考として 本明細書にとり入れるものとする。 All publications, patents and patent applications cited herein are incorporated herein by reference in their entirety.
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006195602A JP4029109B1 (en) | 2006-07-18 | 2006-07-18 | Complex powder of vitamin E and proline and method for producing the same |
| JP2006-195602 | 2006-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008010362A1 true WO2008010362A1 (en) | 2008-01-24 |
Family
ID=38956697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2007/061686 Ceased WO2008010362A1 (en) | 2006-07-18 | 2007-06-05 | Powder of vitamin e/proline complex and method of producing the same |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP4029109B1 (en) |
| WO (1) | WO2008010362A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108033939A (en) * | 2017-12-26 | 2018-05-15 | 上海共晶医药科技有限公司 | Cocrystallization of tocopherol and proline and preparation method thereof |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
| DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
| DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
| DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
| MX2010008138A (en) | 2008-01-25 | 2010-08-10 | Gruenenthal Gmbh | Pharmaceutical dosage form. |
| TWI524904B (en) * | 2008-05-09 | 2016-03-11 | 歌林達股份有限公司 | A method for preparing a solid dosage form for medicine, especially a tablet, and a method for preparing a solid dosage form, especially a pre-load of a tablet |
| CA2765971C (en) | 2009-07-22 | 2017-08-22 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form |
| EP2456425B1 (en) | 2009-07-22 | 2015-10-21 | Grünenthal GmbH | Tamper-resistant dosage form for oxidation-sensitive opioids |
| KR20130137627A (en) | 2010-09-02 | 2013-12-17 | 그뤼넨탈 게엠베하 | Tamper resistant dosage form comprising an anionic polymer |
| EP2611426B1 (en) | 2010-09-02 | 2014-06-25 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
| CN103857386A (en) | 2011-07-29 | 2014-06-11 | 格吕伦塔尔有限公司 | Tamper-resistant tablet providing immediate drug release |
| KR20140053159A (en) | 2011-07-29 | 2014-05-07 | 그뤼넨탈 게엠베하 | Tamper-resistant tablet providing immediate drug release |
| EP2819656A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| PT2838512T (en) | 2012-04-18 | 2018-11-09 | Gruenenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| AU2014273226B2 (en) | 2013-05-29 | 2019-06-27 | Grunenthal Gmbh | Tamper resistant dosage form with bimodal release profile |
| AU2014273227B2 (en) | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
| EP3019157A1 (en) | 2013-07-12 | 2016-05-18 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| CN105934241B (en) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | Preparation of powdered pharmaceutical composition by cryogenic grinding |
| CN106572980A (en) | 2014-05-12 | 2017-04-19 | 格吕伦塔尔有限公司 | Tamper resistant immediate release capsule formulation comprising tapentadol |
| MX2016015417A (en) | 2014-05-26 | 2017-02-22 | Gruenenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping. |
| US20160310429A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58201725A (en) * | 1982-05-19 | 1983-11-24 | Eisai Co Ltd | Composition for preventing browning |
| JPS6058918A (en) * | 1983-09-12 | 1985-04-05 | Advance Res & Dev Co Ltd | Additive for medical purposes |
-
2006
- 2006-07-18 JP JP2006195602A patent/JP4029109B1/en active Active
-
2007
- 2007-06-05 WO PCT/JP2007/061686 patent/WO2008010362A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58201725A (en) * | 1982-05-19 | 1983-11-24 | Eisai Co Ltd | Composition for preventing browning |
| JPS6058918A (en) * | 1983-09-12 | 1985-04-05 | Advance Res & Dev Co Ltd | Additive for medical purposes |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108033939A (en) * | 2017-12-26 | 2018-05-15 | 上海共晶医药科技有限公司 | Cocrystallization of tocopherol and proline and preparation method thereof |
| WO2019128175A1 (en) * | 2017-12-26 | 2019-07-04 | 上海共晶医药科技有限公司 | Cocrystal of tocopherol and proline and preparation method therefor |
| CN108033939B (en) * | 2017-12-26 | 2020-09-11 | 上海共晶医药科技有限公司 | Co-crystal of tocopherol and proline and preparation method thereof |
| JP2021507935A (en) * | 2017-12-26 | 2021-02-25 | コクリスタル ファーマシューティカル テクノロジー(シャンハイ)カンパニー リミテッド | Co-crystal of tocopherol and proline and its manufacturing method |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008024603A (en) | 2008-02-07 |
| JP4029109B1 (en) | 2008-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008010362A1 (en) | Powder of vitamin e/proline complex and method of producing the same | |
| Sun et al. | Calcium binding to herring egg phosphopeptides: Binding characteristics, conformational structure and intermolecular forces | |
| Malison et al. | Chicken foot broth byproduct: A new source for highly effective peptide-calcium chelate | |
| Zhang et al. | Preparation of cattle bone collagen peptides-calcium chelate and its structural characterization and stability | |
| Subaşı et al. | Protein extracts from de-oiled sunflower cake: Structural, physico-chemical and functional properties after removal of phenolics | |
| Peng et al. | Effect of calcium-binding peptide from Pacific cod (Gadus macrocephalus) bone on calcium bioavailability in rats | |
| Weng et al. | Effect of transglutaminase on properties of tilapia scale gelatin films incorporated with soy protein isolate | |
| Wang et al. | Transglutaminase-induced crosslinking of gelatin–calcium carbonate composite films | |
| Makishi et al. | Films based on castor bean (Ricinus communis L.) proteins crosslinked with glutaraldehyde and glyoxal | |
| RS58647B1 (en) | Solid composition comprising iron for use in iron deficient conditions | |
| de Oliveira et al. | Improvement of the characteristics of fish gelatin–gum arabic through the formation of the polyelectrolyte complex | |
| Li et al. | Adhesion properties of camelina protein fractions isolated with different methods | |
| CN107550764A (en) | A kind of preparation method of the oil and fat of sacha inchi water profit Q hoodles of high stability | |
| Chen et al. | Effects of guar gum on adhesion properties of soybean protein isolate onto porcine bones | |
| Nosenko et al. | Rape seeds as a source of feed and food proteins | |
| Hu et al. | The structure and flavor of low sodium seasoning salts in combination with different sesame seed meal protein hydrolysate derived Maillard reaction products | |
| Sun et al. | Structural characterisation of deer sinew peptides as calcium carriers, their promotion of MC3T3-E1 cell proliferation and their effect on bone deposition in mice | |
| Dehsorkhi et al. | Self-assembly of a dual functional bioactive peptide amphiphile incorporating both matrix metalloprotease substrate and cell adhesion motifs | |
| Du et al. | Microencapsulation of Pickering nanoemulsions containing walnut oil stabilized using soy protein–curcumin composite nanoparticles: Fabrication and evaluation of a novel plant-based milk substitute | |
| Men et al. | Preparation, characterization, stability and replenishing calcium ability of Moringa oleifera leaf peptide-calcium chelates | |
| Yang et al. | Chitosan encapsulation soy peptide–calcium promotes calcium absorption and bone health of rats fed a low calcium diet | |
| Zheng et al. | Preparation, structural characterisation, absorption and calcium transport studies of walnut peptide calcium chelate | |
| RU2007135735A (en) | SOLID COSMETIC AND THERAPEUTIC COMPOSITIONS SUITABLE FOR APPLICATION ON HUMAN SKIN AND ARE ABLE TO FORM A GEL IN CONTACT WITH WATER | |
| Racz et al. | Complexation of curcumin using whey proteins to enhance aqueous solubility, stability and antioxidant property | |
| JP6132107B2 (en) | Hydrogel forming material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07744978 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| NENP | Non-entry into the national phase |
Ref country code: RU |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07744978 Country of ref document: EP Kind code of ref document: A1 |